CEA and Calcitonin in MTC: Perioperative Trends and Clinical Significance

Abstract

Carcinoembryonic antigen (CEA) and calcitonin (Ctn) are established tumor markers for medullary thyroid carcinoma (MTC), being used in diagnosis, prognosis, and postoperative surveillance. Nonetheless, their perioperative stability and interpretation are contentious, since alterations in their levels do not necessarily reflect tumor burden or risk of recurrence. Familiarity with these biomarker kinetics is paramount to refine clinical decision-making. This review integrates up-to-date literature on perioperative fluctuations in CEA and Ctn levels, assesses their diagnostic utility across various clinical situations, and considers their influence on treatment plans and long-term consequences. We draw attention to interpreting these biomarkers together, suggest follow-up procedures to reduce the uncertainty of diagnosis and consider possible future paths in biomarker studies to refine MTC treatment.

Introduction

Medullary thyroid carcinoma (MTC) is an uncommon but aggressive neuroendocrine neoplasm originating from the parafollicular C cells of the thyroid gland. Early and precise diagnosis is important for successful management, and biomarkers like carcinoembryonic antigen (CEA) and calcitonin (Ctn) have been utilized for many years to assist in MTC detection and prognosis. Though Ctn is the most sensitive biomarker for MTC, CEA offers supplementary prognostic information, particularly in instances of tumor dedifferentiation. Perioperative changes in these biomarkers tend to make their clinical interpretation challenging, and this makes them unreliable in treatment planning.

This review provides an overview of the perioperative fluctuations of CEA and Ctn, their diagnostic performance, and how one can best optimize their application in practice. With a better grasp of how these markers respond under varied perioperative situations, clinicians will be able to make better patient management and follow-up decisions.

Biological Role and Clinical Utility of CEA and Ctn in MTC

Calcitonin (Ctn)

Calcitonin, a thyroid C cell hormone, is the most important biomarker for MTC. Increased serum Ctn is very specific for MTC, and preoperative levels frequently correspond to tumor load. Postoperative follow-up measurement of Ctn is necessary for determining residual disease or recurrence. Several factors, however, affect Ctn levels, such as renal function, proton pump inhibitors, and stress reactions, which can lead to perioperative variability.

Carcinoembryonic Antigen (CEA)

CEA is a glycoprotein that is traditionally found in several malignancies, of which MTC is one. Although less tumor-specific than Ctn, it does rise with tumor progression and dedifferentiation in MTC. CEA is especially useful in situations when Ctn measurements are not reflecting the burden of disease because of C-cell fatigue or changed tumor biology. Combining Ctn and CEA provides a broader perspective for the monitoring of MTC.

Perioperative Variations in CEA and Ctn

1. Preoperative Biomarker Levels and Prognostic Significance

Preoperative Ctn levels are directly proportional to tumor mass and metastatic spread. A Ctn level exceeding 500 pg/mL strongly indicates regional or distant metastases. Likewise, elevated preoperative CEA levels are linked to more aggressive tumor behavior. However, variations in baseline levels due to physiological or pathological factors necessitate careful interpretation.

2. Intraoperative and Immediate Postoperative Fluctuations

During thyroidectomy for MTC, rapid declines in Ctn are expected if complete tumor resection is achieved. However, some patients exhibit transient postoperative elevations due to physiological stress, inflammatory responses, or incomplete surgical removal. Similarly, CEA may show postoperative fluctuations, although persistent elevation is often a sign of residual disease.

3. Long-Term Postoperative Trends and Clinical Outcomes

Persistent or rising postoperative Ctn levels suggest residual or recurrent MTC, warranting additional imaging and possible reintervention. A complete biochemical response (Ctn <2 pg/mL) correlates with excellent long-term prognosis. In contrast, increasing CEA levels despite stable Ctn concentrations may indicate tumor dedifferentiation, requiring closer follow-up.

Implications for Diagnosis and Treatment Decisions

1. Optimizing Perioperative Biomarker Interpretation

Understanding the interplay between Ctn and CEA fluctuations is crucial for accurate diagnosis and risk stratification. The following clinical considerations can help refine biomarker assessment:

• Rapid Ctn Decline Post-Surgery: Suggests successful tumor removal.

• Persistent or Rising Ctn Levels: Indicates residual disease, metastasis, or recurrence.

• Elevated CEA with Stable Ctn: May signal dedifferentiation, necessitating alternative treatment approaches.

2. Role in Surgical Planning and Extent of Thyroidectomy

Preoperative biomarker levels guide surgical decision-making. Patients with markedly elevated Ctn levels may require total thyroidectomy with central and lateral neck dissection. Perioperative monitoring of these markers ensures adequate surgical clearance and informs the need for additional interventions.

3. Impact on Postoperative Follow-up and Surveillance Strategies

Routine postoperative monitoring of Ctn and CEA is essential for detecting early recurrence. Standardized follow-up protocols include:

• Ctn and CEA Testing Every 3-6 Months in the first two years post-surgery.

• Annual Testing Thereafter in patients with stable or undetectable biomarker levels.

• Imaging Studies (Neck Ultrasound, CT, or MRI) in cases of unexplained biomarker elevation.

Potential Pitfalls and Limitations in Biomarker Use

Despite their clinical utility, CEA and Ctn interpretation is not without challenges. Several factors can confound biomarker readings:

• Non-Specific Ctn Elevation: Conditions such as renal failure, autoimmune diseases, and neuroendocrine tumors may elevate Ctn levels, leading to false positives.

• CEA Variability: Smoking and non-thyroidal malignancies can cause increased CEA levels, reducing specificity.

• Delayed Ctn Decline: Some patients exhibit slow Ctn normalization postoperatively, necessitating extended follow-up.

To address these issues, a multidisciplinary approach integrating biomarker trends, imaging findings, and clinical evaluation is essential.

Future Directions and Innovations in Biomarker Research

Advancements in biomarker technology and molecular diagnostics hold promise for improving MTC management. Emerging areas of interest include:

• Molecular Profiling of MTC: Identifying genetic mutations (e.g., RET proto-oncogene) to refine risk stratification.

• Circulating Tumor DNA (ctDNA) Analysis: A non-invasive alternative for detecting minimal residual disease and early recurrence.

• Artificial Intelligence (AI) in Biomarker Interpretation: Machine learning algorithms could enhance predictive accuracy and clinical decision-making.

Further research is needed to validate these approaches and integrate them into routine clinical practice.

Conclusion

CEA and Ctn are still irreplaceable biomarkers for MTC diagnosis and management. Perioperative changes are problematic to interpret, but an informed grasp of their dynamics adds value to diagnostic accuracy, treatment strategy, and follow-up. The implementation of uniform follow-up regimens and the incorporation of new diagnostic techniques can prevent potential drawbacks and optimize patient results. Advances in biomarker research and precision medicine in more advanced years have the promise to transform MTC care into more individualized and effective treatment approaches.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors